Brain tumors are the leading cause of cancer-related death in children. Of all the pediatric brain tumors, high-grade gliomas (HGG) remain the greatest challenge, with few treatment options available and a five-year survival rate of only 10-30 percent. A potential alternative to conventional treatments is to utilize a patient’s own immune system to attack tumor cells—immunotherapy.

Funded by the Glioblastoma Research Organization, the laboratory of Dr. Steven Millward at the University of Texas MD Anderson Cancer Center has launched The Lee Project, which focuses on the directed evolution of vectors for treating GBM.

The Glioblastoma Research Organization's Project Rush is in collaboration with Lenox Hill Hospital’s Department of Neurosurgery’s Brain Tumor Center in New York City. Project Rush was inspired by the passing of Neil Peart a Canadian-American musician, best known as the drummer and lyricist of the rock band, Rush.

The median age for diagnosis of Glioblastoma is 65, with patient prognosis known to decline with increased age. Christopher Hine, Ph.D., a researcher in the Department of Cardiovascular and Metabolic Sciences at Cleveland Clinic's Lerner Research Institute, has a theory that could explain why.

Project Garcia marks GBMRO’s fourth fully funded Glioblastoma research project and the first in collaboration with Sylvester Comprehensive Cancer Center in Miami, Florida. The project includes novel research that uniquely applies a multiparametric intraoperative strategy to guide tumor resection and identify infiltrating tumor cells responsible for tumor recurrence.